Edition:
India

Theratechnologies Inc (TH.TO)

TH.TO on Toronto Stock Exchange

2.56CAD
28 Oct 2020
Change (% chg)

$-0.08 (-3.03%)
Prev Close
$2.64
Open
$2.54
Day's High
$2.67
Day's Low
$2.51
Volume
100,333
Avg. Vol
135,644
52-wk High
$5.40
52-wk Low
$1.93

Latest Key Developments (Source: Significant Developments)

Theratechnologies Reports Q3 Loss Per Share Of $0.02
Tuesday, 8 Oct 2019 

Oct 8 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR THE THIRD QUARTER OF 2019.Q3 LOSS PER SHARE $0.02.Q3 REVENUE $16.11 MILLION.  Full Article

Theratechnologies Files Application To List On Nasdaq
Monday, 12 Aug 2019 

Aug 12 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES FILES APPLICATION TO LIST ON NASDAQ.THERATECHNOLOGIES INC - THERATECHNOLOGIES WILL FILE A FORM 40-F REGISTRATION STATEMENT WITH UNITED STATES SECURITIES AND EXCHANGE COMMISSION.THERATECHNOLOGIES INC - EXPECTED THAT COMPANY'S COMMON SHARES WILL BE LISTED ON NASDAQ WITHIN NEXT 60 DAYS.THERATECHNOLOGIES INC - WILL MAINTAIN ITS COMMON SHARE LISTING ON TORONTO STOCK EXCHANGE UNDER SYMBOL "TH".  Full Article

Theratechnologies Receives Positive Recommendation From The CHMP For Trogarzo In The European Union
Friday, 26 Jul 2019 

July 26 (Reuters) - Theratechnologies Inc ::THERATECHNOLOGIES RECEIVES POSITIVE RECOMMENDATION FROM THE CHMP FOR TROGARZO® IN THE EUROPEAN UNION.THERATECHNOLOGIES - CHMP IN EUROPE HAS GIVEN A POSITIVE RECOMMENDATION FOR APPROVAL OF TROGARZO FOR TREATMENT OF MULTIDRUG RESISTANT HIV-1.  Full Article

Theratechnologies - European Medicine Agency Grants Theratechnologies An Additional Month To Complete Responses Related To Trogarzo Application
Friday, 24 May 2019 

May 24 (Reuters) - Theratechnologies Inc ::EUROPEAN MEDICINE AGENCY GRANTS THERATECHNOLOGIES AN ADDITIONAL MONTH TO COMPLETE RESPONSES RELATED TO TROGARZO® APPLICATION.THERATECHNOLOGIES INC - ASSUMING A POSITIVE CHMP OPINION, PLANS TO LAUNCH IN GERMANY BEFORE END OF YEAR REMAIN UNCHANGED..THERATECHNOLOGIES INC - WILL SUBMIT RESPONSES TO EMA BY END OF JUNE 2019.THERATECHNOLOGIES - GOT MORE TIME TO ADDRESS NEW QUESTIONS IN REGARD TO ESTABLISHMENT OF REGISTRY TO GATHER LONG-TERM DATA ON PATIENTS TAKING TROGARZO.  Full Article

Theratechnologies Q4 Loss Per Share C$0.02
Thursday, 21 Feb 2019 

Theratechnologies Inc ::THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS FOR FISCAL YEAR 2018.Q4 REVENUE C$18.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF C$19.8 MILLION.Q4 LOSS PER SHARE C$0.02.Q4 EARNINGS PER SHARE ESTIMATE C$0.00 -- REFINITIV IBES DATA.  Full Article

BRIEF-Theratechnologies Announces Ibalizumab Inhibits Hiv-2 In Vitro

* THERATECHNOLOGIES ANNOUNCES IBALIZUMAB INHIBITS HIV-2 IN VITRO Source text for Eikon: Further company coverage: